Chest
Clinical InvestigationsA Longitudinal Study of Lung Function in Nonsmoking Patients With Rheumatoid Arthritis
Section snippets
Recruitment
In 1990, we recruited patients from the RA second-line medication clinic at the Centre for Rheumatic Diseases at Glasgow Royal Infirmary. All patients had RA diagnosed by a consultant rheumatologist, according to American College of Rheumatology criteria,11and were receiving one or more disease-modifying antirheumatoid drugs (DMARDs). Inclusion criteria were lifelong nonsmoking, no documented or recalled evidence of lung disease, and absence of respiratory symptoms on general inquiry at initial
Results
We studied 52 patients (44 women; age range, 29 to 78 years; median, 56 years). Thirty-eight patients were seropositive, and all were receiving DMARD therapy with a median lifetime use of two agents (range, one to four agents). The DMARDs used and the number of patients prescribed them are as follows: IM gold (n = 25), sulfasalazine (n = 22), penicillamine (n = 11), hydroxychloroquine (n = 8), methotrexate (n = 4), and azathioprine (n = 3). Only three patients had been solely administered
Discussion
There have been a considerable number of cross-sectional studies looking at the prevalence of pulmonary abnormalities in patients with RA who were not known to have lung involvement. The older studies451718192021222324used PFTs to detect the abnormalities, whereas in more recent times this has been combined with HRCT of the thorax6725262728; all studies concur in that a high prevalence of abnormality (35 to 65%) can be found. By contrast, 27% of our population had pulmonary function
Conclusions
We have demonstrated that, within a population of patients with RA selected as lifelong nonsmokers with no respiratory symptoms, the prevalence of pulmonary function abnormality is higher than expected when compared with a reference population, but did not increase over 10 years. Assessed by group means and SRs, both Dlco and RV/TLC became significantly abnormal in 2000 when compared with reference values. However, rates of change of pulmonary function variables were not significantly different
References (35)
Rheumatoid arthritis
Rheum Dis Clin North Am
(1990)- et al.
Pulmonary dysfunction in rheumatoid disease
Chest
(1973) - et al.
Airway disease in a subset of nonsmoking rheumatoid patients: characterization of the disease and evidence for an autoimmune pathogenesis
Am J Med
(1982) - et al.
Pulmonary function in patients receiving long-term low-dose methotrexate
Chest
(1996) - et al.
An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis
Q J Med
(1992) - et al.
Obstructive pulmonary disease in rheumatoid arthritis
Arthritis Rheum
(1976) - et al.
Airways obstruction in rheumatoid arthritis
Ann Rheum Dis
(1979) - et al.
Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings
Am J Respir Crit Care Med
(1998) - et al.
High resolution computed tomography of the lungs in patients with rheumatoid arthritis
Rheumatol Int
(1999) - et al.
Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study
Br J Rheumatol
(1996)
An 8-year follow-up study of pulmonary function in patients with rheumatoid arthritis
Rheumatol Int
A longitudinal study of pulmonary function in patients with rheumatoid arthritis treated with gold and D-penicillamine
Br J Rheumatol
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
Arthritis Rheum
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis
Q J Med
Epidemiology Standardization Project (American Thoracic Society)
Am Rev Respir Dis
Third National Health and Nutrition Examination Survey, 1988–1994, NHANES III laboratory data file
Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists
Respir Med
Cited by (28)
Predictors of airway and parenchymal lung abnormalities in patients with rheumatoid arthritis
2021, Egyptian RheumatologistCitation Excerpt :Pulmonary function test (PFT) abnormality has been reported in RA patients especially seropositive cases and are more likely to have obstructive and restrictive abnormalities [7]. However, most abnormalities remain clinically insignificant and asymptomatic patients with PFT abnormalities generally do not show physiologic progression over 10 years [8]. High-resolution computed tomography (HRCT) of the chest forms the basis of investigation [9].
Complex obstructive lung disease – A diagnostic and management conundrum
2020, Respiratory Medicine Case ReportsCitation Excerpt :In a Taiwanese retrospective cohort study, the incidence of COPD in individuals with RA was found to be 1.74 fold higher than the non-RA population; however because they used a national database that did not include information regarding tobacco use, they could not assess the effect of smoking (Shen). A prospective study of 52 non-smoking patients with “active” RA (as defined by the current use of DMARD therapy) in the United Kingdom found that there was an increased prevalence of obstructive pattern found on PFTs which did not worsen over a 10-year follow-up period [7]. These individuals did demonstrate a decline in DLCO over the same time period, which may have been attributable to their RA therapy.
Longitudinal changes in pulmonary function and respiratory impedance of rheumatoid arthritis
2019, Respiratory Physiology and NeurobiologyCitation Excerpt :It is likely that pulmonary functions remained in a relatively stable condition during observation periods in our RA patients who were able to undergo the follow-up pulmonary function test and Zrs measurement. Similar findings were reported for a non-smoking RA cohort (Fuld et al., 2003). The Rrs of the last assessment was significantly lower than that at the baseline at all frequencies between 4 and 36 Hz (Fig. 1A).
FEV<inf>1</inf> over time in patients with connective tissue disease-related bronchiolitis
2013, Respiratory MedicineCitation Excerpt :Immunomodulatory therapies are often used in attempts to halt the progressive fibrous luminal narrowing of constrictive bronchiolitis (CB) or the transmural inflammation of cellular or follicular bronchiolitis in patients with connective tissue disease- (CTD-) related bronchiolitis. Pulmonary function tests (PFTs) are an essential part of standard monitoring in patients with CTD-related bronchiolitis; however, little is known about the natural history (or the effects of immunomodulatory therapy on lung function over time) of bronchiolar disease in these patients.1–7 Data on longitudinal trends in lung function is essential for patient management decisions and for designing therapeutic trials.
What is the outcome of RA in 2011 and can we predict it?
2011, Best Practice and Research: Clinical RheumatologyCitation Excerpt :About one-third of the patients had already developed RA-ILD at baseline. In another study, including a small study population of non-smoking patients with RA without a history of respiratory disorders, the prevalence of pulmonary lung function test abnormalities was higher than expected but did not change over a 10 year period [27]. In a retrospective cohort study using annual cross-sectional data collected from 1985 to 2006 from the US Veteran’s Health Administration system, an increase in RA lung disease was observed, increasing from 19 to 22 cases per 1000 over 10 years [28].
Rheumatoid arthritis-associated airway disease: longitudinal pulmonary function behavior
2024, Jornal Brasileiro de Pneumologia
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: [email protected]).